#USA #Woburn, Massachusetts #HCC Treatment #Sirtex Medical #SIR-Spheres

Sirtex Medical's Groundbreaking DOORwaY90 Study

In a significant advancement for cancer treatment, the DOORwaY90 study by Sirtex Medical has established a new benchmark in the management of unresectable hepatocellular carcinoma (HCC) using SIR-Spheres®. This pioneering study has reported remarkable outcomes, achieving a 100% local tumor control rate and a 99% overall response rate (ORR) among evaluated patients.

The DOORwaY90 study, a landmark twelve-month investigation, demonstrates the effectiveness of Selective Internal Radiation Therapy (SIRT) when administered with personalized dosimetry. With these promising findings, Sirtex Medical has reached a pivotal moment in the treatment of HCC, a challenging form of liver cancer that often does not respond well to conventional therapies.

Key Findings

Dr. Armeen Mahvash, an interventional radiologist at MD Anderson Cancer Center and one of the lead researchers of the DOORwaY90 study, highlighted that all evaluable patients exhibited a response to treatment, resulting in an unprecedented 100% local control of tumors. Notably, the study achieved a complete response (CR) rate of 90%, with durable responses observed in 75% of patients lasting over six months.

The median duration of response was recorded at 295 days, affirming the potential of SIR-Spheres® Y-90 in delivering lasting results while preserving liver function. Over 95% of patients maintained stable liver functionality throughout the twelve-month period, showcasing the ability of personalized dosimetry to elicit aggressive tumor responses without compromising hepatic reserves.

Presentation and Reception of Results

These groundbreaking results were recently shared during an oral presentation at the annual meeting of the Society of Interventional Radiology (SIR) held in Toronto, Canada. The reception was overwhelmingly positive, as they emphasize the therapeutic potential of Y-90 in liver-focused treatments – positioning it not only as a viable option but as a new gold standard in the field of oncological care.

Matt Schmidt, CEO of Sirtex Medical, expressed expectations that the outcomes from the DOORwaY90 study would reshape the expectations surrounding Y-90 therapy. The impressive 99% overall response rate and consistent tumor control redefines what can be anticipated from treatment plans for patients suffering from unresectable HCC.

Looking Ahead

SIR-Spheres® Y-90 holds the unique distinction of being the only radioactive embolization therapy approved by the FDA for treating metastatic colorectal cancer (mCRC) in the liver and unresectable HCC in the United States. As more data emerges and clinical practice evolves, there is an optimistic outlook on how personalized dosimetry and advanced therapies can dramatically enhance patient outcomes.

For more information about SIR-Spheres and integrating personalized dosimetry into clinical practice, individuals can contact Sirtex directly or visit their official website. Sirtex Medical remains committed to advancing minimally invasive oncological approaches globally, with operations spanning across the USA, Australia, Europe, and Asia.